Gumarontinib

Gumarontinib is a pharmaceutical drug used for the treatment of cancer. In China, it was conditionally approved in 2023 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation.

Gumarontinib is a selective mesenchymal–epithelial transition (MET) inhibitor.